Jim Nightingale has been promoted from Senior VP for Business Development and Strategic Alliances to President of drug development company Bend Research. Rod Ray is stepping down as President but will remain as CEO and chairman of the board. David Lyon, current VP of Research will assume the Business Development responsibilities.
Until two years ago, Bend performed research exclusively for Pfizer, and Ray credits Nightingale with developing the strategy that allowed the company to become a CRO with more than 70 clients.
According to Bend, its inhalation delivery platform, based on a spray drying method of particle engineering, is “capable of decoupling aerosol performance from API properties, including API with non-ideal solid forms and biotherapeutics.” The company offers manufacturing services as well as formulation development.
Read the Bend Research press release.
